Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 4 recruiting now full pipeline small index

Chronic Hepatitis B: full-pipeline trial registry

4 of 16 indexed Chronic Hepatitis B trials are currently recruiting.

Corpus placement: #1,060 of 28,707 conditions by registered trial count.

16 US clinical trials · 4 currently recruiting · #1,060 of 28,707 conditions by registered trial count

Chronic Hepatitis B: 16 US clinical trials tracked, 4 recruiting.

Chronic Hepatitis B is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 6 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Gilead Sciences, running 8 of these trials.

Enrollment posture brief

Registry condition chronic-hepatitis-b

OPEN 4 | RECR 25% | LATE 6 | EARLY 9 | RANK #1060 | SPON 8

Nearest open-share peer: Abdominal Cancer (25% recruiting · 8 trials)

Adolescent62.5%Alcohol Intoxication56.3%AL Amyloidosis43.8%Chronic Hepatitis B (this)25%Allergy18.8%
Open-enrollment share among volume-matched conditions near Chronic Hepatitis B

Chronic Hepatitis B lists 4 open slots (25% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Chronic Hepatitis B on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Chronic Hepatitis B is recruiting below its size-band peers.

    4 of 16 indexed trials (25%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. One sponsor concentrates Chronic Hepatitis B research.

    Gilead Sciences accounts for 8 of 16 trials (50%). 6 distinct sponsors appear on at least one study for this condition label.

  3. Typical Chronic Hepatitis B enrolment sits around 150 participants.

    Median target enrolment is 150 among the 15 trials that report a genuine target (sentinel values excluded). 6 of those (40%) plan for fewer than 100 participants.

  4. Chronic Hepatitis B research is mostly interventional.

    15 interventional and 1 observational studies make up this index (93.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 12Phase 27Phase 35Phase 41

Open and recent trials

16 total, page 1 of 1

RECRUITING Phase 2 150 participants

Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection

Gilead Sciences

NCT02932150

RECRUITING Phase 2 50 participants

VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT06092333

RECRUITING Phase 2 10 participants

Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis B

University of Maryland, Baltimore

NCT06154278

RECRUITING Phase 1 10 participants

TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B

University of Maryland, Baltimore

NCT04843852

ACTIVE NOT RECRUITING Phase 3 981 participants

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

GlaxoSmithKline

NCT05630807

ACTIVE NOT RECRUITING Phase 3 857 participants

Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)

GlaxoSmithKline

NCT05630820

ACTIVE NOT RECRUITING Phase 3 90 participants

Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection

Gilead Sciences

NCT01651403

COMPLETED Phase 4 751 participants

Efficacy & Safety of Tenofovir Disoproxil Fumarate (TDF) Plus Peginterferon α-2a (Peg-IFN) Versus TDF or Peg-IFN Monotherapy in Chronic Hepatitis B

Gilead Sciences

NCT01277601

COMPLETED Phase 3 490 participants

Study to Evaluate Efficacy and Safety of Switching From TDF to TAF in Adults With Chronic Hepatitis B Who Are Virologically Suppressed

Gilead Sciences

NCT02979613

COMPLETED Phase 2 195 participants

Safety and Efficacy of GS-4774 in Combination With Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Participants With Chronic Hepatitis B (CHB) and Who Are Currently Not on Treatment

Gilead Sciences

NCT02174276

COMPLETED Phase 2 192 participants

Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated

Gilead Sciences

NCT02579382

COMPLETED Phase 2 162 participants

Study To Evaluate Safety and Efficacy of Vesatolimod for the Treatment of Chronic Hepatitis B Virus in Virally-Suppressed Participants

Gilead Sciences

NCT02166047

COMPLETED 100 participants

Evaluation of Chronic HBV Patients w/Evidence of HBV Replication and Normal or Minimally Elevated Liver Transaminases.

Gilead Sciences

NCT00263614

COMPLETED Phase 1 64 participants

A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B

AusperBio Therapeutics

NCT05717686

COMPLETED Phase 2 14 participants

Add-on Peginterferon Following Nucleos(t)Ide Analogue Treatment

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NCT02364336

COMPLETED Phase 3

A Phase III Study of Entecavir vs Lamivudine in Chronic Hepatitis B Subjects With Incomplete Response to Lamivudine

Bristol-Myers Squibb

NCT00036608

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 7
Phase 3 5
Phase 4 1

Named interventions

Most-linked intervention names on Chronic Hepatitis B records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Placebo Drug
4 trials
TDF Drug
3 trials
Vesatolimod Drug
2 trials
TDF Placebo Drug
2 trials
TAF Drug
2 trials
Bepirovirsen Drug
2 trials
Placebo Other
2 trials
GS-4774 Biological
1 trials

US sites by state

Facility locations filed on Chronic Hepatitis B trials. A trial with sites in several states counts in each.

Maryland 13 trials
California 12 trials
New York 7 trials
Massachusetts 6 trials
Texas 5 trials
Pennsylvania 5 trials
Florida 5 trials
Michigan 4 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Chronic Hepatitis B page

16 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 4 Chronic Hepatitis B trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Gilead Sciences sponsors the most Chronic Hepatitis B trials on record, review their full trial history before evaluating a specific study. See Gilead Sciences's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Chronic Hepatitis B condition card totals 16 registered trials; most-linked intervention Placebo; top US site state Maryland. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.